Disease progression patterns of bevacizumab responders with recurrent malignant gliomas

Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who r...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncol Lett
Autores principales: Kim, Ju-Hwi, Jung, Tae-Young, Hwang, Eu Chang, Jung, Sung-Hoon, Jung, Shin, Kim, In-Young, Jang, Woo-Youl, Moon, Kyung-Sub, Lee, Kyung-Hwa, Kim, Seul-Kee
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5588053/
https://ncbi.nlm.nih.gov/pubmed/28927109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6630
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares